Do analysts prefer GNLX or ABVC?

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 514.33%. Given Genelux's stronger consensus rating and higher probable upside, research analysts plainly believe Genelux is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GNLX or ABVC?

ABVC BioPharma has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,138.12 -$32.15M -$0.85 N/A ABVC BioPharma $510K 61.18 -$7.91M -$0.40 N/A

Is GNLX or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% ABVC BioPharma N/A -62.46% -39.99%

Do analysts prefer ETHZ or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ETHZ or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Flag Ship Acquisition N/A -185.71% -83.12% ABVC BioPharma N/A -62.46% -39.99%

Do analysts rate VTVT or ABVC?

vTv Therapeutics presently has a consensus price target of $56.67, indicating a potential upside of 75.01%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VTVT or ABVC more profitable?

vTv Therapeutics' return on equity of 3.96% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% ABVC BioPharma N/A -62.46% -39.99%

Is CRDL or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% ABVC BioPharma N/A -62.46% -39.99%

Do analysts prefer ABVC or ENGN?

enGene has a consensus target price of $11.05, suggesting a potential upside of 490.67%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is ABVC or ENGN more profitable?

enGene's return on equity of -56.06% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% enGene N/A -56.06% -45.64%

ABVC BioPharma (ABVC) Competitors

$1.20 -0.05 (-4.00%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.21 +0.01 (+0.83%)

As of 07/20/2026 07:34 PM Eastern

Compare

ABVC vs. GNLX, ETHZ, VTVT, CRDL, and ENGN

Should you buy ABVC BioPharma stock or one of its competitors? MarketBeat compares ABVC BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ABVC BioPharma include Genelux (GNLX), Flag Ship Acquisition (ETHZ), vTv Therapeutics (VTVT), Cardiol Therapeutics (CRDL), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does ABVC BioPharma compare to Genelux?

Genelux (NASDAQ:GNLX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 514.33%. Given Genelux's stronger consensus rating and higher probable upside, research analysts plainly believe Genelux is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma's return on equity of -62.46% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
ABVC BioPharma	N/A	-62.46%	-39.99%

ABVC BioPharma has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,138.12	-$32.15M	-$0.85	N/A
ABVC BioPharma	$510K	61.18	-$7.91M	-$0.40	N/A

In the previous week, Genelux's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Genelux	Neutral
ABVC BioPharma	Neutral

Genelux has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ABVC BioPharma beats Genelux on 7 of the 13 factors compared between the two stocks.

How does ABVC BioPharma compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

ABVC BioPharma's return on equity of -62.46% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
ABVC BioPharma	N/A	-62.46%	-39.99%

In the previous week, Flag Ship Acquisition's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Flag Ship Acquisition	Neutral
ABVC BioPharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Flag Ship Acquisition has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	26.27	-$6.17M	-$159.65	N/A
ABVC BioPharma	$510K	61.18	-$7.91M	-$0.40	N/A

Flag Ship Acquisition has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ABVC BioPharma beats Flag Ship Acquisition on 6 of the 10 factors compared between the two stocks.

How does ABVC BioPharma compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

vTv Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

vTv Therapeutics presently has a consensus price target of $56.67, indicating a potential upside of 75.01%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

vTv Therapeutics' return on equity of 3.96% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
ABVC BioPharma	N/A	-62.46%	-39.99%

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for vTv Therapeutics and 0 mentions for ABVC BioPharma. vTv Therapeutics' average media sentiment score of 0.67 beat ABVC BioPharma's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Positive
ABVC BioPharma	Neutral

ABVC BioPharma has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	125.08	-$26.97M	-$0.93	N/A
ABVC BioPharma	$510K	61.18	-$7.91M	-$0.40	N/A

Summary

vTv Therapeutics beats ABVC BioPharma on 10 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Cardiol Therapeutics had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 0 mentions for ABVC BioPharma. Cardiol Therapeutics' average media sentiment score of 0.34 beat ABVC BioPharma's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
ABVC BioPharma	Neutral

Cardiol Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 588.26%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
ABVC BioPharma	$510K	61.18	-$7.91M	-$0.40	N/A

Cardiol Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ABVC BioPharma's return on equity of -62.46% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
ABVC BioPharma	N/A	-62.46%	-39.99%

Summary

Cardiol Therapeutics beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to enGene?

ABVC BioPharma (NASDAQ:ABVC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

enGene has a consensus target price of $11.05, suggesting a potential upside of 490.67%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 5 more articles in the media than ABVC BioPharma. MarketBeat recorded 5 mentions for enGene and 0 mentions for ABVC BioPharma. enGene's average media sentiment score of 0.08 beat ABVC BioPharma's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
ABVC BioPharma	Neutral
enGene	Neutral

enGene's return on equity of -56.06% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
enGene	N/A	-56.06%	-45.64%

ABVC BioPharma has higher revenue and earnings than enGene. ABVC BioPharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	61.18	-$7.91M	-$0.40	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

ABVC BioPharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

Summary

enGene beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.50M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-3.00	20.49	27.07	23.94
Price / Sales	61.18	300.33	512.71	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.31	7.92	10.63	6.14
Net Income	-$7.91M	$23.81M	$3.60B	$331.74M
7 Day Performance	-10.45%	-1.09%	-1.24%	-1.82%
1 Month Performance	-11.11%	2.56%	1.09%	-1.45%
1 Year Performance	-65.91%	42.16%	23.66%	16.32%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.5167 of 5 stars	$1.20 -4.0%	N/A	-64.2%	$32.50M	$510K	N/A	30	Gap Up
GNLX Genelux	2.1913 of 5 stars	$2.91 +0.7%	$18.00 +518.6%	-12.0%	$130.48M	$10K	N/A	10
ETHZ Flag Ship Acquisition	N/A	$6.80 +4.9%	N/A	N/A	$129.28M	$4.11M	N/A	7	Gap Down
VTVT vTv Therapeutics	2.9959 of 5 stars	$32.69 +2.5%	$55.33 +69.3%	+93.1%	$128.77M	$36.84M	N/A	9	Positive News High Trading Volume
CRDL Cardiol Therapeutics	1.9293 of 5 stars	$1.11 -3.5%	$8.50 +665.8%	+3.8%	$127.93M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. GNLX, ETHZ, VTVT, CRDL, and ENGN

How does ABVC BioPharma compare to Genelux?

Summary

How does ABVC BioPharma compare to Flag Ship Acquisition?

Summary

How does ABVC BioPharma compare to vTv Therapeutics?

Summary

How does ABVC BioPharma compare to Cardiol Therapeutics?

Summary

How does ABVC BioPharma compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. GNLX, ETHZ, VTVT, CRDL, and ENGN

How does ABVC BioPharma compare to Genelux?

Do analysts prefer GNLX or ABVC?

Is GNLX or ABVC more profitable?

Which has higher valuation & earnings, GNLX or ABVC?

Does the media prefer GNLX or ABVC?

Which has more risk and volatility, GNLX or ABVC?

Do institutionals and insiders have more ownership in GNLX or ABVC?

Summary

How does ABVC BioPharma compare to Flag Ship Acquisition?

Is ETHZ or ABVC more profitable?

Does the media refer more to ETHZ or ABVC?

Do analysts prefer ETHZ or ABVC?

Which has stronger earnings & valuation, ETHZ or ABVC?

Which has more volatility & risk, ETHZ or ABVC?

Do insiders & institutionals believe in ETHZ or ABVC?

Summary

How does ABVC BioPharma compare to vTv Therapeutics?

Which has more volatility & risk, VTVT or ABVC?

Do analysts rate VTVT or ABVC?

Is VTVT or ABVC more profitable?

Do institutionals and insiders believe in VTVT or ABVC?

Does the media refer more to VTVT or ABVC?

Which has preferable valuation and earnings, VTVT or ABVC?

Summary

How does ABVC BioPharma compare to Cardiol Therapeutics?

Does the media refer more to CRDL or ABVC?

Do analysts prefer CRDL or ABVC?

Which has higher earnings & valuation, CRDL or ABVC?

Which has more volatility and risk, CRDL or ABVC?

Do insiders and institutionals believe in CRDL or ABVC?

Is CRDL or ABVC more profitable?

Summary

How does ABVC BioPharma compare to enGene?

Do institutionals & insiders have more ownership in ABVC or ENGN?

Do analysts prefer ABVC or ENGN?

Does the media prefer ABVC or ENGN?

Is ABVC or ENGN more profitable?

Which has higher earnings and valuation, ABVC or ENGN?

Which has more risk & volatility, ABVC or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools